News
Drug halts muscle loss tied to weight-loss injections, early trials show
Apitegromab, a new muscle-preserving drug, may prevent the so-called "Ozempic butt" effect in patients using GLP-1 obesity medications. Phase 2 results show a 48% reduction in muscle wasting among trial participants within 16 weeks.